Wednesday, April 5, 2023

Grand Rounds: John M. Kane, M.D.

10:30 AM to 12:00 PM

Rachel Upjohn Building Auditorium and


“The Management of Poor/Partial Response and Prevention of Relapse in Early Phase Schizophrenia: An EPINET Perspective” 

COI: None
CME, APA, Social Work credits


Photo of John Kane, M.D.

John M. Kane, M.D.

Professor, Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Professor, Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Co-Director & Professor, Institute of Behavioral Science, Feinstein Institutes for Medical Research

John M. Kane, MD, served as chair of psychiatry at Zucker Hillside Hospital for 34 years and chair of psychiatry at the Zucker School of Medicine for 12 years. Dr. Kane received his BA from Cornell University and his MD from New York University School of Medicine. He is a diplomate of the American Board of Psychiatry and Neurology. 

Dr. Kane has been the principal investigator of 23 National Institutes of Health (NIH) grants focusing on schizophrenia, such as psychobiology and treatment, recovery and improving the quality and cost of care, as well as the application of digital technology. He has authored more than 875 scientific papers in peer-reviewed journals and has been consistently ranked by Thomson Reuters in the top 1% of researchers in his field, based on citations of his work.

Research focus

Dr. Kane is committed to implementing new technologies that enhance access to care, quality of care, and outcomes while increasing cost effectiveness for schizophrenia treatment. He has been working on the development of new strategies for patient engagement, adherence monitoring and clinical decision making using advanced technologies such as live two-way video and similar telecommunications. He works closely with numerous academic, state and federal agencies as well as advocacy groups to ensure feasibility and sustainability of new models of technology-enhanced care.

Dr. Kane was a pioneer in the study of first episode schizophrenia and conducted groundbreaking work with clozapine for treatment resistant schizophrenia. He has continuously focused on both therapeutic and adverse effects of psychotropic drugs, thereby informing benefit-to-risk considerations. Dr. Kane also devotes his efforts to standardizing the outcome measurements in psychiatric research and helping to ensure the translation of research into clinical practice. Since the beginning of his residency at Zucker Hillside Hospital in Glen Oaks in 1971, Dr. Kane has committed his career to unraveling the mysteries of this brain disorder.


Stephan Taylor, M.D.

Albert J. Silverman, M.D., C.M., Research Professor of Psychiatric Disorders, Medical School
Professor of Psychiatry
Associate Chair for Research and Research Regulatory Affairs
Director, Residency Research Track Training Program
Director, PREP Early Psychosis Clinic
Adjunct Professor of Psychology